Literature DB >> 22262588

The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program.

Susan Forrow1, Daniel M Campion, Lisa J Herrinton, Vinit P Nair, Melissa A Robb, Marcus Wilson, Richard Platt.   

Abstract

The US Food and Drug Administration's Mini-Sentinel pilot program is developing an organizational structure as well as principles and policies to govern its operations. These will inform the structure and function of the eventual Sentinel System. Mini-Sentinel is a collaboration that includes 25 participating institutions. We describe the program's current organizational structure and its major principles and policies. The organization includes a coordinating center with program leadership provided by a principal investigator; a planning board and subcommittees; an operations center; and data, methods, and protocol cores. Ad hoc workgroups are created as needed. A privacy panel advises about protection of individual health information. Principles and policies are intended to ensure that Mini-Sentinel conforms to the principles of fair information practices, protects the privacy of individual health information, maintains the security and integrity of data, assures the confidentiality of proprietary information, provides accurate and timely communications, prevents or manages conflicts of interest, and preserves respect for intellectual property rights.
Copyright © 2012 John Wiley & Sons, Ltd.

Mesh:

Year:  2012        PMID: 22262588     DOI: 10.1002/pds.2242

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  15 in total

1.  How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?

Authors:  Andre M Samuel; Vinay K Rathi; Jonathan N Grauer; Joseph S Ross
Journal:  Clin Orthop Relat Res       Date:  2015-11-19       Impact factor: 4.176

Review 2.  Clinical research data warehouse governance for distributed research networks in the USA: a systematic review of the literature.

Authors:  John H Holmes; Thomas E Elliott; Jeffrey S Brown; Marsha A Raebel; Arthur Davidson; Andrew F Nelson; Annie Chung; Pierre La Chance; John F Steiner
Journal:  J Am Med Inform Assoc       Date:  2014-03-28       Impact factor: 4.497

3.  Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users.

Authors:  Ryan M Carnahan; Joshua J Gagne; Christian Hampp; Charles E Leonard; Sengwee Toh; Candace C Fuller; Sean Hennessy; Laura Hou; Noelle M Cocoros; Genna Panucci; Tiffany Woodworth; Austin Cosgrove; Aarthi Iyer; Elizabeth A Chrischilles
Journal:  Pharmaceut Med       Date:  2019-02

4.  Chart validation of inpatient ICD-9-CM administrative diagnosis codes for acute myocardial infarction (AMI) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database.

Authors:  Eric M Ammann; Marin L Schweizer; Jennifer G Robinson; Jayasheel O Eschol; Rami Kafa; Saket Girotra; Scott K Winiecki; Candace C Fuller; Ryan M Carnahan; Charles E Leonard; Cole Haskins; Crystal Garcia; Elizabeth A Chrischilles
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-02-15       Impact factor: 2.890

5.  Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia.

Authors:  Meijia Zhou; Shirley V Wang; Charles E Leonard; Joshua J Gagne; Candace Fuller; Christian Hampp; Patrick Archdeacon; Sengwee Toh; Aarthi Iyer; Tiffany Siu Woodworth; Elizabeth Cavagnaro; Catherine A Panozzo; Sophia Axtman; Ryan M Carnahan; Elizabeth A Chrischilles; Sean Hennessy
Journal:  Epidemiology       Date:  2017-11       Impact factor: 4.822

6.  Fast-Tracking Health Data Standards Development and Adoption in Real-World Settings: A Pilot Approach.

Authors:  Allison F Dennis; P Jon White; Teresa Zayas-Cabán
Journal:  Appl Clin Inform       Date:  2021-08-11       Impact factor: 2.762

7.  Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE.

Authors:  Faraz S Ahmad; Iben M Ricket; Bradley G Hammill; Lisa Eskenazi; Holly R Robertson; Lesley H Curtis; Cecilia D Dobi; Saket Girotra; Kevin Haynes; Jorge R Kizer; Sunil Kripalani; Mathew T Roe; Christianne L Roumie; Russ Waitman; W Schuyler Jones; Mark G Weiner
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-05-29

8.  The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist.

Authors:  Nicholas Moore
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

9.  Using a Handheld Device for Patient Data Collection: A Pilot for Medical Countermeasures Surveillance.

Authors:  Matthew F Daley; Kristin Goddard; Melissa McClung; Arthur Davidson; Gretchen Weiss; Ted Palen; Carsie Nyirenda; Richard Platt; Brooke Courtney; Marsha E Reichman
Journal:  Public Health Rep       Date:  2016 Jan-Feb       Impact factor: 2.792

10.  Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States.

Authors:  Efe Eworuke; Nicole Haug; Marie Bradley; Austin Cosgrove; Tancy Zhang; Elizabeth C Dee; Sruthi Adimadhyam; Andrew Petrone; Hana Lee; Tiffany Woodworth; Sengwee Toh
Journal:  JNCI Cancer Spectr       Date:  2021-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.